Despite promising results in preclinical research, the early clinical trials with both agonistic TRAIL receptor antibodies as well as recombinant TRAIL have been disappointing, probably due to suboptimal agonistic activity of the selected compounds and the occurrence of resistance mechanisms within cancer cells [55]. The gene discussed is TNFSF10; the disease is cancer.